GGrantIndex
Sort

78,016 grants matching breast cancer

Imaging tumor and T cell responses to metabolic and immune modulation therapy

$712,992
Ronald G Blasberg · Sloan-Kettering Inst Can Research · R01 · FY2017 · CA

Imaging tumor and T cell responses to metabolic and immune modulation therapy

$712,992
Ronald G Blasberg · Sloan-Kettering Inst Can Research · R01 · FY2018 · CA

Modeling Best Approaches for Cardiovascular Disease Prevention in Cancer Survivors

$712,969
Juan P Wisnivesky · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · CA

Ontario Familial Breast Cancer Registry

$712,896
Irene L. Andrulis · Cancer Care Ontario · U01 · FY2008 · CA

A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma

$712,796
Prasad S. Adusumilli · Sloan-Kettering Inst Can Research · R01 · FY2022 · CA

A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma

$712,796
Prasad S. Adusumilli · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA

ROLE OF RUNX1 REARRANGEMENTS IN TRIPLE-NEGATIVE BREAST CANCER PROGRESSION AND IMMUNE EVASION

$712,770
University Of Pittsburgh - Of The Commonwealth System Of Higher Education · · FY2022 · Department of the Army

CANCER PREVENTION AND CONTROL TRAINING GRANT

$712,733
University Of Arizona · R25 · FY2001 · CA

Small molecule enhancers of tumor immunity targeting the LPA5 GPCR

$712,726
Gabor J Tigyi · University Of Tennessee Health Sci Ctr · R01 · FY2024 · CA

Protein Tyrosine Dephosphorylation & Signal Transduction

$712,640
Nicholas K Tonks · Cold Spring Harbor Laboratory · R01 · FY2010 · CA

Radiomic and genomic predictors of breast cancer risk

$712,593
Weiva Sieh · Icahn School Of Medicine At Mount Sinai · R01 · FY2021 · CA

MODELING BREAST DEVELOPMENT AND CANCER IN A NOVEL ANIMAL MODEL

$712,535
University Of California, Davis · · FY2010 · Department of the Army

Development of Best-in-Class Pol-Theta Inhibitors

$712,514
Richard T Pomerantz · Thomas Jefferson University · R01 · FY2024 · CA

The impact of lifestyle and genetic factors on mammographic density in a cohort of Hispanic women

$712,453
Sara Lindstroem · University Of Washington · R01 · FY2022 · CA

Cherokee Nation Native American Research Center for Health

$712,440
Sohail Imran Khan · Cherokee Nation · S06 · FY2018 · GM

Upright, Low-dose, High-resolution, 3D Breast CT

$712,431
Andrew Karellas · University Of Arizona · R01 · FY2021 · CA

GENERAL CLINICAL RESEARCH CENTER

$712,339
University Of Kentucky · M01 · FY2001 · RR

Mechanisms of Ischemic Kidney Injury and Repair

$712,313
Joseph Vincent Bonventre · Brigham And Women'S Hospital · R01 · FY2024 · DK

Novel Markers for Disease Outcome in Breast Cancer

$712,287
Stefan Ambs · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA

Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study

$712,278
Demetrius Albanes · Division Of Cancer Epidemiology And Genetics · ZIA · FY2022 · CA

The Role of Fgf Signaling in Vertebrate Development

$712,253
Mark B Lewandoski · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA

IGF::OT::IGF R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH)AWARD OF TASK ORDER "OPTIMIZATION AND FURTHER DEVELOPMENT OF MESOTHELIN VACCINE FOR THE PREVENTION OF OVARIAN CANCER"

$712,240
Nathalie Scholler · Sri International · N01 · FY2016 · CA

Multilevel Interventions to Increase Adherence to Lung Cancer Screening

$712,200
Karen J Wernli · Kaiser Foundation Research Institute · R01 · FY2021 · CA

Center for Development of Medications and Biologics for Treatment of the Pregnant Patient and Fetus

$712,148
Gary D Hankins · University Of Texas Med Br Galveston · U54 · FY2015 · HD

Human natural killer cells: Advancing biology and clinical applications

$712,108
Michael A Caligiuri · Beckman Research Institute/City Of Hope · R35 · FY2019 · CA